Enhanced Immunoreactivity of TIMP-2 in the Stromal Compartment of Tumor as a Marker of Favorable Prognosis in Ovarian Cancer Patients

Journal of Histochemistry and Cytochemistry

Volumn 60, Issue 7, 2012, Pages 491-501

  Hałoń, Agnieszka ^a   Nowak Markwitz, Ewa ^b   Donizy, Piotr ^a   Matkowski, Rafał ^a,c   Maciejczyk, Adam ^c   Gansukh, Tserenchunt ^d   Györffy, Balázs ^e,f   Spaczyński, Marek ^b   Zabel, Maciej ^b   Lage, Hermann ^a,f   Surowiak, Paweł ^a,c,f  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^d MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

immunocytochemistry; immunohistochemistry; ovarian cancer; predictive factor; prognostic factor; TIMP 2

Indexed keywords

CELL MARKER; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOPOTECAN; ANTINEOPLASTIC AGENT; TIMP2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG SENSITIVITY; ENDOMETRIAL STROMAL TUMOR; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAPAROTOMY; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE; BIOSYNTHESIS; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STROMA CELL; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL COMPARTMENTATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84865849647     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155412446978     Document Type: Article

References (31)

1. Baker AH,Edwards DR,Murphy G.Metalloproteinase inhibitors: biological actions and therapeutic opportunities.J Cell Sci. 2002;115:3719-3727.
2. Bigelow RL,Williams BJ,Carroll JL,Daves LK,Cardelli JA.TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro.Breast Cancer Res Treat. 2009;117:31-44.
3. Bourboulia D,Jensen-Taubman S,Rittler MR,Han HY,Chatterjee T,Wei B,Stetler-Stevenson WG.Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.Am J Pathol. 2011;179:2589-2600.
4. Butler G,Butler M,Atkinson S,Will H,Tamura T,Schade van Westrum S,Crabbe T,Clements J,d'Ortho MP,Murphy G.The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study.J Biol Chem. 1998;273:871-880.
5. Davidson B,Goldberg I,Gotlieb WH,Kopolovic J,Ben-Baruch G,Nesland JM,Reich R.The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.Mol Cell Endocrinol. 2002;187:39-45.
6. Fernandez CA,Butterfield C,Jackson G,Moses MA.Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor.J Biol Chem. 2003;278:40989-40995.
7. Furuya M,Ishikura H,Kawarada Y,Ogawa Y,Sakuragi N,Fujimoto S,Yoshiki T.Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.Gynecol Oncol. 2000;78:106-112.
8. Gershtein ES,Levkina NV,Digayeva MA,Laktionov KP,Tershkina IV,Kushlinsky NE.Matrix metalloproteinases 2, 7 and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.Bull Exp Biol Med. 2010;149:628-631.
9. Györffy B,Surowiak P,Kiesslich O,Denkert C,Schäfer R,Dietel M,Lage H.Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.Int J Cancer. 2006;118:1699-1712.
10. Hayakawa T,Yamashita K,Tanzawa K,Uchijima E,Iwata K.Growth promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells: a possible new growth factor in serum.FEBS Lett. 1992;298:29-32.
11. Jiang Y,Goldberg ID,Shi YE.Complex roles of tissue inhibitors of metalloproteinases in cancer.Oncogene. 2002;21:2245-2252.
12. Kikkawa F,Tamakoshi K,Nawa A,Shibata K,Yamagata S,Yamagata T,Suqanuma N.Positive correlation between inhibitors of matrix metalloproteinases 1 and matrix metalloproteinases in malignant ovarian tumor tissues.Cancer Lett. 1997;120:109-115.
13. Kim TJ,Rho SB,Choi YL,Choi CH,Lee JW,Bae DS,Ahn G,Lee JH,Kim BG.High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.Hum Pathol. 2006;37:906-913.
14. Kinoshita T,Sato H,Okada A,Ohuchi E,Imai K,Okada Y,Seiki M.TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads.J Biol Chem. 1998;273:16098-16103.
15. Kowalski P,Surowiak P,Lage H.Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.Mol Ther. 2005;11:508-522.
16. Lu KV,Jong KA,Rajasekaran AK,Cloughesy TF,Mischel PS.Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.Lab Invest. 2004;84:8-20.
17. Manenti L,Paganoni P,Floriani I,Landoni F,Torri V,Buda A,Taraboletti G,Labianca R,Belotti D,Giavazzi R.Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.Eur J Cancer. 2003;39:1948-1956.
18. Materna V,Liedert B,Homale J,Lage H.Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.Int J Cancer. 2005;115:393-402.
19. Materna V,Stege A,Surowiak P,Priebsch A,Lage H.RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.Biochem Biophys Res Commun. 2006;348:153-157.
20. Materna V,Surowiak P,Markwitz E,Spaczynski M,Drag-Zalesinska M,Zabel M,Lage H.Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients.Oncol Rep. 2007;17:505-516.
21. Okamoto T,Nui R,Yamada S.Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary.Mol Hum Reprod. 2003;9:569-575.
22. Rauvala M,Puistola U,Turpeenniemi-Hujanen T.Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.Gynecol Oncol. 2005;99:656-663.
23. Remmele W,Stegner HE.Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.Pathologe. 1987;8:138-140.
24. Sakata K,Shigemasa K,Nagai N,Ohama K.Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.Int J Oncol. 2000;17:673-681.
25. Shimizu Y,Kamoi S,Amada S,Akiyama F,Silverberg SG.Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.Cancer. 1998;82:893-901.
26. UICC TNM classification of malignant tumors. Sobin LHWittekind C, ed. New York: Wiley-Liss; 1997:.
27. Sternlicht MD,Werb Z.How matrix metalloproteinases regulate cell behavior.Ann Rev Cell Dev Biol. 2001;17:463-516.
28. Surowiak P,Materna V,Kaplenko I,Spaczynski M,Dietel M,Lage H,Zabel M.Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapsed ovarian cancer tissue samples.Histol Histopathol. 2006;25:131-139.
29. Surowiak P,Materna V,Kaplenko I,Spaczynski M,Dolinska-Krajewska B,Gebarowska E,Dietel M,Zabel M,Lage H.ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinoma and correlates with resistance to cisplatin and clinical outcome.Clin Cancer Res. 2006;12:7149-7158.
30. Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC, et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.J Natl Cancer Inst. 2000;92:205-216.
31. Yoshida H,Ishiko O,Sumi T,Matsumoto Y,Oqita S.Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas.Int J Oncol. 2001;19:537-542.